169 related articles for article (PubMed ID: 18311535)
1. Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma.
Kazama T; Faria SC; Uchida Y; Ito H; Macapinlac HA
Ann Nucl Med; 2008 Feb; 22(2):111-4. PubMed ID: 18311535
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced pneumonitis detected earlier by 18F-FDG-PET than by high-resolution CT: a case report with non-Hodgkin's lymphoma.
Yamane T; Daimaru O; Ito S; Nagata T; Yoshiya K; Fukaya N; Ito S; Imai T; Uchida H
Ann Nucl Med; 2008 Oct; 22(8):719-22. PubMed ID: 18982476
[TBL] [Abstract][Full Text] [Related]
3. Early detection value of
Zhao M; Zhang W
Ann Hematol; 2019 Apr; 98(4):909-914. PubMed ID: 30460376
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 18F-FDG Pet/CT and CT: diagnosis performance in lymphoma patient after treatment.
Chiewvit S; Thephamongkhol K; Ubolnuch K; Pooliam J; Phongsawat N; Chiewvit P
J Med Assoc Thai; 2014 Jan; 97(1):85-94. PubMed ID: 24701734
[TBL] [Abstract][Full Text] [Related]
6. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118
[TBL] [Abstract][Full Text] [Related]
7. Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma.
Hagtvedt T; Seierstad T; Lund KV; Løndalen AM; Bogsrud TV; Smith HJ; Geier OM; Holte H; Aaløkken TM
Acta Radiol; 2015 Feb; 56(2):152-8. PubMed ID: 24585944
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D
Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212
[TBL] [Abstract][Full Text] [Related]
10. [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy.
Kalkanis D; Stefanovic A; Paes F; Escalon MP; Serafini A; Lossos IS
Leuk Lymphoma; 2009 Jun; 50(6):904-11. PubMed ID: 19455459
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
Zhao J; Qiao W; Wang C; Wang T; Xing Y
Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT.
Tsuji K; Kishi S; Tsuchida T; Yamauchi T; Ikegaya S; Urasaki Y; Fujiwara Y; Ueda T; Okazawa H; Kimura H
J Magn Reson Imaging; 2015 Jun; 41(6):1601-7. PubMed ID: 25111444
[TBL] [Abstract][Full Text] [Related]
13. Nonossifying fibroma can mimic residual lymphoma in FDG PET: additional value of combined PET/CT.
von Falck C; Rosenthal H; Gratz KF; Galanski M
Clin Nucl Med; 2007 Aug; 32(8):640-2. PubMed ID: 17667441
[TBL] [Abstract][Full Text] [Related]
14. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
[TBL] [Abstract][Full Text] [Related]
16. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Qiu L; Chen Y; Wu J
Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin's disease--a useful tool for monitoring pulmonary toxicity and disease activity.
Buchler T; Bomanji J; Lee SM
Haematologica; 2007 Nov; 92(11):e120-1. PubMed ID: 18024389
[TBL] [Abstract][Full Text] [Related]
18. The impact of FDG positron emission tomography imaging on the management of lymphomas.
Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL
Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743
[TBL] [Abstract][Full Text] [Related]
19. FDG-PET/CT is a pivotal imaging modality to diagnose rare intravascular large B-cell lymphoma: case report and review of literature.
Colavolpe C; Ebbo M; Trousse D; Khibri H; Franques J; Chetaille B; Coso D; Ouvrier MJ; Gastaud L; Guedj E; Schleinitz N
Hematol Oncol; 2015 Jun; 33(2):99-109. PubMed ID: 24850057
[TBL] [Abstract][Full Text] [Related]
20. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]